Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial.

Nina BuchteleMichael SchwameisChristian SchoergenhoferUlla DerhaschnigChrista FirbasRudolf KarchDarrell NixRoman SchenkBernd Jilma

Published in: British journal of clinical pharmacology (2020)

Parenteral injection of dutogliptin was safe and subcutaneous bioavailability is excellent. DPP-IV inhibition increased dose dependently to >86% over 24 hours after multiple doses of 120 mg dutogliptin.

Keyphrases

open label
phase iii
study protocol
clinical trial
phase ii
double blind
placebo controlled